Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI

ConclusionsThese data further emphasize that osimertinib should be a standard of care in patients with pretreated EGFR T790M-positive NSCLC.

Source: Targeted Oncology - July 20, 2020 Category: Cancer & Oncology Source Type: research